Characterization of circRNAs in established osimertinib resistant NSCLC cell lines
Drug resistance is a dauting challenge and an urgent problem to be solved in the treatment of non-small-cell lung cancer (NSCLC). Osimertinib is a third-generation EGFR-TKI, improving the efficacy and life quality of patients, However, the inevitable resistance after long-term use of osimertinib often leads to treatment failure. Cell lines are key tools for basic and preclinical studies. Few osimertinib resistant cell lines have been established so far. Osimertinib resistant cell lines were established by gradually increasing drug concentration. circRNA expression profile was identified via RNA-seq of HCC827, HCC827-OR, H1975 and H1975-OR cells.